Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987530 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29047045 | 0.90 | MDM4 (0.49) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL30802551 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29367497 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL598209 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29624621 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL119575 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL12677569 | 0.90 | MDM4 (0.49) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL119565 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29355082 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6534627-B1 | Using FMOC (9-fluorenylmethyloxycarbonyl) and tert-butyl containing compounds as protecting group; efficiency and storage stability | RESEARCH CORPORATION TECNOLOGIES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| US-6040422-A | REACTING A FLUOROFORMAMIDINIUM SALT WITH AN N-AMINO PROTECTED, OPTIONALLY SIDE CHAIN PROTECTED AMINO ACID; THEN REACTING PRODUCT WITH A CARBOXY PROTECTED AMINO ACID; FOR COMPOUNDS WITH LONG TERM STORAGE STABILITY | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |
| US-5750767-A | REACTING PROTECTED AMINO ACID WITH FLUOROFORMAMIDINIUM SALT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5712418-A | FLUOROFORMAMIDINIUM SALTS AS FLUORINATION AGENTS TO FORM PEPTIDES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-01-27 | — | — | US | disclosed |
| WO-1996004297-A9 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1996-05-02 | — | — | WO | disclosed |
| WO-1996004297-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0496836-B1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RES CORP TECHNOLOGIES INC (US) | 1995-06-14 | — | — | EP | disclosed |
| US-5360928-A | Synthesis and use of amino acid fluorides as peptide coupling reagents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0496836-A4 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1993-05-05 | — | — | EP | disclosed |
| EP-0496836-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS. | RES CORP TECHNOLOGIES INC (US) | 1992-08-05 | — | — | EP | disclosed |
| WO-1991005564-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FGFR3 | MDM4 602/4885TP53 109/4885CASP3 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.